CO6260011A2 - Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico - Google Patents
Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumaticoInfo
- Publication number
- CO6260011A2 CO6260011A2 CO10019661A CO10019661A CO6260011A2 CO 6260011 A2 CO6260011 A2 CO 6260011A2 CO 10019661 A CO10019661 A CO 10019661A CO 10019661 A CO10019661 A CO 10019661A CO 6260011 A2 CO6260011 A2 CO 6260011A2
- Authority
- CO
- Colombia
- Prior art keywords
- amide
- hydroxy
- methyl
- carboxylic acid
- antagonist
- Prior art date
Links
- VCEGDBURKQJDAX-UHFFFAOYSA-N 4-hydroxy-4-methylpiperidine-1-carboxylic acid Chemical compound CC1(O)CCN(C(O)=O)CC1 VCEGDBURKQJDAX-UHFFFAOYSA-N 0.000 title abstract 3
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 4
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 2
- 102000010909 Monoamine Oxidase Human genes 0.000 abstract 2
- 108010062431 Monoamine oxidase Proteins 0.000 abstract 2
- 239000000674 adrenergic antagonist Substances 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract 2
- 230000002093 peripheral effect Effects 0.000 abstract 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- DOIKFFGWUPLXGA-UHFFFAOYSA-N 4-methoxy-7-morpholin-4-yl-1,3-benzothiazol-2-amine Chemical compound C1=2SC(N)=NC=2C(OC)=CC=C1N1CCOCC1 DOIKFFGWUPLXGA-UHFFFAOYSA-N 0.000 abstract 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 abstract 1
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 abstract 1
- 229940122459 Glutamate antagonist Drugs 0.000 abstract 1
- 229940122439 Hydroxylase inhibitor Drugs 0.000 abstract 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 abstract 1
- 102100037346 Substance-P receptor Human genes 0.000 abstract 1
- XNBRWUQWSKXMPW-UHFFFAOYSA-N Tozadenant Chemical compound C1=2SC(NC(=O)N3CCC(C)(O)CC3)=NC=2C(OC)=CC=C1N1CCOCC1 XNBRWUQWSKXMPW-UHFFFAOYSA-N 0.000 abstract 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 abstract 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 abstract 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 abstract 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003825 glutamate receptor antagonist Substances 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229940125794 sodium channel blocker Drugs 0.000 abstract 1
- 239000003195 sodium channel blocking agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proveen métodos para tratar el trastorno por estrés postraumático con la (4-metoxi-7-morfolin-4-iI-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin-1-carboxílico. Además, se proveen métodos para mejorar la capacidad de recuperación con la (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil- piperidin-1-carboxílico. También se proveen métodos para diagnosticar en un paciente el trastorno por estrés postraumático. 1.- Un método para tratar un paciente al que se le ha diagnosticado trastorno por estrés postraumático, caracterizado porque comprende administrar a dicho paciente una cantidad terapéuticamente eficaz de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del ácido 4-hidroxi-4-metil-piperidin- 1-carboxílico. 2.- El método de la reivindicación 1, caracterizado porque dicho método además comprende coadministrar una cantidad terapéuticamente eficaz de, al menos, otro agente seleccionado entre benzodiazepina, un inhibidor selectivo de la recaptación de serotonina (ISRS), un inhibidor de la recaptación de serotonina-norepinefrina (SNRI), un inhibidor de la recaptación de norepinefrina (NRI), un antagonista de la serotonina 5-hidroitriptamina1A (5HTIA), un inhibidor de la dopamina β-hidroxilasa, un antagonista del receptor de adenosina A2A, un inhibidor de monoamina oxidasa (MAOI), un bloqueador de los canales de sodio (Na), un bloqueador de los canales de calcio, un antagonista del receptor alfa adrenérgico central o periférico, un agonista alfa adrenérgico central, un antagonista del receptor beta adrenérgico central o periférico, un antagonista del receptor NK-1, un antagonista del factor de liberación de corticotropina (CRF), un antidepresivo atípico/antipsicótico, un tricíclico, un anticonvulsivo, un antagonista de glutamato, un agonista del ácido gamma-aminobutírico (GABA), y un agonista parcial D2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93503507P | 2007-07-23 | 2007-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6260011A2 true CO6260011A2 (es) | 2011-03-22 |
Family
ID=40281808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10019661A CO6260011A2 (es) | 2007-07-23 | 2010-02-19 | Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20090082341A1 (es) |
| EP (1) | EP2182803A4 (es) |
| JP (1) | JP2010534674A (es) |
| CN (1) | CN101873799A (es) |
| AU (1) | AU2008279169A1 (es) |
| BR (1) | BRPI0814672A2 (es) |
| CA (1) | CA2708323C (es) |
| CO (1) | CO6260011A2 (es) |
| MX (1) | MX2010000938A (es) |
| NZ (1) | NZ583191A (es) |
| RU (1) | RU2500401C2 (es) |
| WO (1) | WO2009015236A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2491067C2 (ru) * | 2007-08-06 | 2013-08-27 | Байотай Терапис, Инк | Способы лечения зависимости |
| WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| WO2018059531A1 (zh) * | 2016-09-30 | 2018-04-05 | 苏州晶云药物科技有限公司 | 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途 |
| WO2022167778A1 (en) | 2021-02-02 | 2022-08-11 | Haiku Therapeutics Ltd | Ebselen as adenosine receptor modulator |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL153278A0 (en) * | 2000-06-21 | 2003-07-06 | Hoffmann La Roche | Benzothiazole derivatives |
| WO2003022283A1 (en) * | 2001-09-13 | 2003-03-20 | Schering Corporation | Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic |
| AU2004244906A1 (en) * | 2003-06-10 | 2004-12-16 | Kyowa Hakko Kirin Co., Ltd. | A method of treating an anxiety disorder |
| AU2004309279B2 (en) * | 2003-12-26 | 2010-07-15 | Kyowa Kirin Co., Ltd. | Thiazole derivative |
| GB0403155D0 (en) * | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| EA011279B1 (ru) * | 2004-05-24 | 2009-02-27 | Ф. Хоффманн-Ля Рош Аг | (4-метокси-7-морфолин-4-илбензотиазол-2-ил)-амид 4-гидрокси-4-метилпиперидин-1-карбоновой кислоты |
| RU2328977C2 (ru) * | 2007-01-15 | 2008-07-20 | Наталья Леонидовна Бундало | Способ диагностики посттравматического стрессового расстройства (птср) |
| AU2008279091A1 (en) * | 2007-07-23 | 2009-01-29 | Biotie Therapies, Inc | Treatment of post-traumatic stress disorder |
-
2008
- 2008-07-23 MX MX2010000938A patent/MX2010000938A/es not_active Application Discontinuation
- 2008-07-23 JP JP2010518365A patent/JP2010534674A/ja active Pending
- 2008-07-23 NZ NZ583191A patent/NZ583191A/en not_active IP Right Cessation
- 2008-07-23 BR BRPI0814672-1A2A patent/BRPI0814672A2/pt not_active IP Right Cessation
- 2008-07-23 EP EP08796507A patent/EP2182803A4/en not_active Withdrawn
- 2008-07-23 WO PCT/US2008/070934 patent/WO2009015236A1/en active Application Filing
- 2008-07-23 CN CN200880108162A patent/CN101873799A/zh active Pending
- 2008-07-23 AU AU2008279169A patent/AU2008279169A1/en not_active Abandoned
- 2008-07-23 CA CA2708323A patent/CA2708323C/en not_active Expired - Fee Related
- 2008-07-23 US US12/178,509 patent/US20090082341A1/en not_active Abandoned
- 2008-07-23 RU RU2010106023/15A patent/RU2500401C2/ru not_active IP Right Cessation
-
2010
- 2010-02-19 CO CO10019661A patent/CO6260011A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008279169A1 (en) | 2009-01-29 |
| WO2009015236A1 (en) | 2009-01-29 |
| CN101873799A (zh) | 2010-10-27 |
| EP2182803A4 (en) | 2010-09-01 |
| NZ583191A (en) | 2012-06-29 |
| MX2010000938A (es) | 2010-07-01 |
| RU2010106023A (ru) | 2011-08-27 |
| JP2010534674A (ja) | 2010-11-11 |
| CA2708323C (en) | 2013-09-24 |
| BRPI0814672A2 (pt) | 2014-09-30 |
| US20090082341A1 (en) | 2009-03-26 |
| EP2182803A1 (en) | 2010-05-12 |
| CA2708323A1 (en) | 2009-01-29 |
| RU2500401C2 (ru) | 2013-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6260011A2 (es) | Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico | |
| ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
| CO4900058A1 (es) | Terapia de combinacion para el tratamiento de psicosis | |
| AU2003289854A1 (en) | Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents | |
| CL2011001735A1 (es) | Composicion farmaceutica que comprende: a) el inhibidor de sglt2 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)-bencil]-benceno, b) el inhibidor de dppiv linagliptina y c) un tercer agente antidiabetico que es clorhidrato de metformina; y su uso para tratar la diabetes mellitus tipo 2. | |
| CR6436A (es) | Inhibidores de la receptacion de monoaminas para el tratamiento de trastornos del snc | |
| RS54328B1 (en) | MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS | |
| ECSP067019A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
| CO6260078A2 (es) | Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros | |
| BRPI0513812B8 (pt) | método para produzir uma composição líquida que compreende 13c-piruvato hiperpolarizado, composição, uso da mesma, radical, e, uso do radical | |
| RU2007103313A (ru) | Комбинация бупропина и другого состава для эффективной потери веса | |
| GT201000153A (es) | Agonistas novedosos de los receptores de glucocorticoides | |
| CR9849A (es) | Agonistas del receptor gamma activado por el proliferador de peroxisomas para la mejora de la funcion cognitiva en pacientes con apolipoproteina e4 negativa | |
| ECSP055885A (es) | Derivados de carbostirilo e inhibidores de la recaptacion de serotonina que sirven para el tratamiento de desordenes en el humor | |
| CL2008002247A1 (es) | Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros. | |
| RU2012152922A (ru) | Лечение психологических состояний с применением антагонистов м1-мускариновых рецепторов | |
| PE20080332A1 (es) | Metodos para mejoramiento de funcion cognitiva | |
| JP2012036212A5 (es) | ||
| JP2009542819A5 (es) | ||
| MX2020002741A (es) | Uso de gaboxadol en el tratamiento de narcolepsia. | |
| Rubio et al. | Reboxetine adjunct for partial or nonresponders to antidepressant treatment | |
| AR074302A1 (es) | Trans-clomifeno para el sindrome metabolico y la diabetes mellitus tipo 2.. metodo | |
| PE20090524A1 (es) | Composicion farmaceutica que comprende la combinacion de una triazolobenzodiazepina y un agente inhibidor selectivo de la recaptura de serotonina | |
| ATE536877T1 (de) | 7-keto-dhea zur anwendung in der psychiatrie | |
| AR060312A1 (es) | Metodos para regular renalasa (monoamina oxidasa c) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |